Literature DB >> 33688391

Potential Effects of Immunosuppression on Oxidative Stress and Atherosclerosis in Kidney Transplant Recipients.

Marlena Kwiatkowska1, Urszula Oldakowska-Jedynak1, Ewa Wojtaszek1, Tomasz Glogowski1, Jolanta Malyszko1.   

Abstract

Chronic kidney disease is a public health problem that, depending on the country, affects approximately 8-13% of the population, involving both males and females of all ages. Renal replacement therapy remains one of the most costly procedures. It is assumed that one of the factors influencing the course of chronic kidney disease might be oxidative stress. It is believed that the main mediators of oxidative stress are reactive oxygen species (ROS). Transiently increased concentrations of ROS play a significant role in maintaining an organism's homeostasis, as they are part of the redox-related signaling, and in the immune defense system, as they are produced in high amounts in inflammation. Systemic oxidative stress can significantly contribute to endothelial dysfunction along with exaggeration of atherosclerosis and development of cardiovascular disease, the leading cause of mortality in patients with kidney disease. Moreover, the progression of chronic kidney disease is strictly associated with the atherosclerotic process. Transplantation is the optimal method for renal replacement therapy. It improves better quality of life and prolongs survival compared with hemodialysis and peritoneal dialysis; however, even a successful transplantation does not correct the abnormalities found in chronic kidney disease. As transplantation reduces the concentration of uremic toxins, which are a factor of inflammation per se, both the procedure itself and the subsequent immunosuppressive treatment may be a factor that increases oxidative stress and hence vascular sclerosis and atherosclerotic cardiovascular disease. In the current work, we review the effect of several risk factors in kidney transplant recipients as well as immunosuppressive therapy on oxidative stress.
Copyright © 2021 Marlena Kwiatkowska et al.

Entities:  

Mesh:

Year:  2021        PMID: 33688391      PMCID: PMC7920738          DOI: 10.1155/2021/6660846

Source DB:  PubMed          Journal:  Oxid Med Cell Longev        ISSN: 1942-0994            Impact factor:   6.543


  59 in total

1.  Antioxidant capacity in renal transplant patients.

Authors:  M Chrzanowska; J Kamińska; M Głyda; G Duda; E Makowska
Journal:  Pharmazie       Date:  2010-05       Impact factor: 1.267

Review 2.  Role of nuclear factor kappaB in cardiovascular health and disease.

Authors:  Kim Van der Heiden; Simon Cuhlmann; Le A Luong; Mustafa Zakkar; Paul C Evans
Journal:  Clin Sci (Lond)       Date:  2010-02-23       Impact factor: 6.124

3.  Effects of Rituximab on Atherosclerotic Biomarkers in Kidney Transplant Recipients.

Authors:  N Aliyeva; E Demir; S U Akgul; S Temurhan; A R Ucar; A B Dirim; A Bayraktar; N M Catikkas; A Erol; Y Caliskan; H Yazici; B Yelken; F O Savran; A Turkmen
Journal:  Transplant Proc       Date:  2019-02-08       Impact factor: 1.066

4.  Effect of different calcineurin inhibitors on AOPP and TAS after kidney transplantation.

Authors:  Josef Zadrazil; Pavel Strebl; Karel Krejcí; Vladko Horcicka; Pavel Horák; Jitka Vostálová; Adéla Zdarilová; Markéta Kajabová; Petr Schneiderka
Journal:  Clin Biochem       Date:  2010-01-18       Impact factor: 3.281

5.  Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.

Authors:  H J Eisen; J Kobashigawa; R C Starling; D F Pauly; A Kfoury; H Ross; S-S Wang; B Cantin; A Van Bakel; G Ewald; S Hirt; H Lehmkuhl; A Keogh; M Rinaldi; L Potena; A Zuckermann; G Dong; C Cornu-Artis; P Lopez
Journal:  Am J Transplant       Date:  2013-02-22       Impact factor: 8.086

6.  Long-term survival of renal transplant recipients in the United States after acute myocardial infarction.

Authors:  C A Herzog; J Z Ma; A J Collins
Journal:  Am J Kidney Dis       Date:  2000-07       Impact factor: 8.860

7.  Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens.

Authors:  Abdulgaffar Vural; Mahmut Ilker Yilmaz; Kayser Caglar; Ahmet Aydin; Alper Sonmez; Tayfun Eyileten; Cengizhan Acikel; Bulent Gulec; Orhan Kozak; Koksal Oner
Journal:  Am J Nephrol       Date:  2005-05-27       Impact factor: 3.754

8.  Modulation factors of oxidative status in stable renal transplantation.

Authors:  J M Moreno; M C Ruiz; N Ruiz; I Gomez; F Vargas; C Asensio; A Osuna
Journal:  Transplant Proc       Date:  2005-04       Impact factor: 1.066

9.  Effect of calcineurin inhibitors on low-density lipoprotein oxidation.

Authors:  F Cofan; M Cofan; B Campos; R Guerra; J-M Campistol; F Oppenheimer
Journal:  Transplant Proc       Date:  2005-11       Impact factor: 1.066

10.  Post-transplantation plasma malondialdehyde is associated with cardiovascular mortality in renal transplant recipients: a prospective cohort study.

Authors:  Manuela Yepes-Calderón; Camilo G Sotomayor; Rijk O B Gans; Stefan P Berger; Henri G D Leuvenink; Dimitrios Tsikas; Ramón Rodrigo; Gerjan J Navis; Stephan J L Bakker
Journal:  Nephrol Dial Transplant       Date:  2020-03-01       Impact factor: 5.992

View more
  1 in total

1.  The Identification of Candidate Biomarkers and Pathways in Atherosclerosis by Integrated Bioinformatics Analysis.

Authors:  Youwei Lu; Xi Zhang; Wei Hu; Qianhong Yang
Journal:  Comput Math Methods Med       Date:  2021-11-10       Impact factor: 2.238

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.